Validation of miRNA signatures for the early detection of lung cancer

• Conditions: Malignant neoplasm of bronchus and lung; C34

• Registration Number: DRKS00013647
• Lead Sponsor: Hummingbird Diagnostics GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-02-05
• Study Completion: 2022-04-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 310

Inclusion Criteria

1. Male or female with presumable pathological findings through X-ray/CT
2. Signed informed consent
3. Patient is at least 18 years old

Exclusion Criteria

1. History of other primary malignancies
2. Medication that influences the immune system (e.g. immunosuppressive drugs)
3. Patient is younger than 18 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Validation of a previously identified signature of blood-based miRNA biomarkers for the identification of lung tumors. After measuring miRNA expression levels, it will be tested whether the signature can be used to discriminate between the two cohorts and if the results are comparable to previous tests.

Secondary Outcome Measures

Name	Time	Method
Testing the potential of a previously identified signature of blood-based miRNA biomarkers for lung cancer screening.